Powered by purpose
Our mission is to make biological medicine available for everyone, everywhere
We strive to achieve our mission through innovative R&D, strategic partnerships, and a relentless focus on quality and efficiency
Who We Are
ABYOLO is a global biosimilar company committed to making biological medicines accessible and affordable to everyone, everywhere. We leverage cutting-edge technology and innovative solutions to bridge healthcare gaps. Our agile, asset-light approach allows us to adapt swiftly and maintain operational efficiency. Our team, with extensive experience and rational thinking, drives the next growth phase in the pharmaceutical industry. >>
What We Do
We specialize in the efficient R&D of biosimilars, using latest technology, including AI, ML, digitalization and automation. Our streamlined processes, free from legacy constraints, enable faster R&D and lower costs. We ensure global approval through a single dossier and strategic partnerships, with a vertically integrated process from cell line development to regulatory approval. >>
Why We Do It
Our mission is to make biosimilars affordable and accessible to all. By focusing on cost-efficiency and technological innovation, we aim to improve global health outcomes. As the biosimilars market grows, our approach reduces development costs and enhances access, leading to significant savings and better health for a larger patient population.
Company
Founded by industry visionaries, ABYOLO is rapidly advancing in the biosimilar market.
Our journey began with a commitment to revolutionize the biosimilar industry, driven by a team of experts with decades of experience in drug development, regulatory navigation, business and global market expansion.
Today, we operate from our strategic headquarters in Switzerland.
Mission
Our mission is to make biological medicine affordable and available to everyone, everywhere.
We strive to achieve this through innovative R&D, strategic partnerships, and a relentless focus on quality and efficiency.
Vision
Our vision is to be a leading global biosimilar company.
Leadership
-
With a PhD in management, Damian brings 17 years of financial sector leadership. Expertise in regulatory navigation and operational optimization sets him apart. A seasoned professional in international expansions, he lays a robust foundation for growth. Strategic advisory skills and focus on cost optimization ensure quality assurance in competitive markets with a proven track record of successful innovation.
-
Sarfaraz is a professor and a biosimilar pioneer having created the team and establishing the first US biosimilar company, and securing approval of multiple biosimilars. He has been serving as an advisor to regulatory agencies including the FDA, EMA and MHRA and assised the US Senate in amending the BPCIA.
-
Sesselja is professor and an experienced leader with 25 years of experience in drug development and research. She led R&D departments and several global biosimilar programs from beginning to filing. Her expertise extends to quality projects, laboratory building, and manufacturing facility development.
-
Sönke offers 17+ years in financial strategy. His adept use of technology streamlines financial operations, ensuring robust growth and scalability. A trusted leader, he excels in safeguarding assets and enhancing investor relations for sustainable corporate success.
Values
At ABYOLO, we are driven by a set of core values that shape our culture and guide our actions:
Entrepreneurial: We are entrepreneurs, always at the forefront using innovative technologies. This mindset gives us the confidence to explore new solutions and push the boundaries of what is possible.
Rationality: Our focus is on bringing biological medicine to everyone, everywhere, and we promote biosimilars with a rational approach, increasing the accessibility.
Commitment: We are dedicated to positively impacting global health by making biosimilars accessible and affordable to a larger patient population.
Corporate Sustainability
ABYOLO is committed to sustainable practices across all aspects of our operations. Our approach includes:
Global Affordability and Access: Offering affordable biosimilar for everyone, everywhere.
Digitalization and Automation: Reducing environmental impact through efficient use of resources.
Sustainable Manufacturing: Implementing green practices in our manufacturing processes to minimize waste and energy consumption.
Office Locations
Headquarters:
Switzerland